EscharEx is a Enzyme owned by MediWound, and is involved in 3 clinical trials, which were completed.

The drug candidate removes the eschar from the burns. The proteolytic enzymes degrade necrotic tissue. These enzymes are involved in regulation of cell maturation and multiplication, collagen synthesis. The drug candidate may aid in removal of dead tissues, prevents local infection and sepsis thereby enables initiation of wound healing.

The revenue for EscharEx is expected to reach a total of $85m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the EscharEx NPV Report.

EscharEx is originated and owned by MediWound.

EscharEx Overview

EscharEx is under development for the debridement of chronic and other hard to heal venous leg ulcers, diabetic foot ulcers (lower extremity), traumatic/post operative wounds. It is applied topically. The drug candidate is a proteolytic enzyme. The development of the drug candidate is based on proteolytic enzymatic technology.

MediWound Overview

MediWound is a biopharmaceutical company that develops, manufactures and markets novel therapeutics to address the unmet needs in the areas of chronic, severe burns, other hard-to-heal wounds and for connective tissue disorders. The company uses its patented proteolytic enzyme technology for the development of its products. The company offers NexoBrid, a drug for the removal of damaged or dead tissue, namely, eschar, in adults with severe burns (deep partial and full-thickness thermal burns). EscharEX, pipeline drug candidate for the removal of damaged, dead or infected tissues from chronic wounds; MWPC003, a pre-clinical candidate for treating connective tissue Disorders. The company markets NexoBrid in the Europe and Israel through its own commercial organization and in Russia, Peru, India, Bangladesh, South Korea, Argentina through distributors. MediWound is headquartered in Yavne, Israel.

The company reported revenues of (US Dollars) US$23.8 million for the fiscal year ended December 2021 (FY2021), an increase of 9.2% over FY2020. The operating loss of the company was US$11.2 million in FY2021, compared to an operating loss of US$8.8 million in FY2020. The net loss of the company was US$13.6 million in FY2021, compared to a net loss of US$9.2 million in FY2020. The company reported revenues of US$5.8 million for the third quarter ended September 2022, an increase of 24.3% over the previous quarter.

Quick View – EscharEx

Report Segments
  • Innovator
Drug Name
  • EscharEx
Administration Pathway
  • Topical
Therapeutic Areas
  • Dermatology
  • Metabolic Disorders
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.